FeesSafety
Pluang+

Gouverneur Bancorp reports $3.1M Q4 loss amid strategic balance sheet restructuring.

Company Fundamentals
28 Oct 2026, 23:15 WIB
GlobeNewsWire
View Source
Bearish
Gouverneur Bancorp reports $3.1M Q4 loss amid strategic balance sheet restructuring.

Gouverneur Bancorp announced a net loss of $3.1 million for Q4 2026, driven by a strategic balance sheet restructuring that included selling $24 million in securities and $20 million in loan participations, causing significant pretax losses. Despite the loss, adjusted net income was positive, reflecting ongoing loan growth and improved net interest margins. The restructuring aims to reduce funding costs and enhance future earnings, with benefits expected to materialize over time. The company also reported a full-year net loss of $2.3 million but showed adjusted net income of $984,000 for fiscal 2026.

Gouverneur Bancorp's fiscal 2026 results provide context for financial sector performance. For readers following Financials, here is Pluang's market snapshot as of Oct 29, 2026 03:01 WIB: 85 of 142 US Financials stocks rose while 56 fell. Deutsche Bank AG (DB) gained 4.27% to USD 33.49 with 63% buy orders, CleanSpark Inc (CLSK) rose 4.21% to USD 8.54, and Robinhood Markets, Inc. (HOOD) dropped 4.20% to USD 90.59 with 59% buy orders. Typical hold times range from 23 to 81 days on Pluang.

More News

China's coffee market to reach $8.04B by 2032, driven by cafe culture and specialty coffee growth.

China's coffee market to reach $8.04B by 2032, driven by cafe culture and specialty coffee growth.

China's coffee market is projected to grow from $5.8 billion in 2026 to $8.04 billion by 2032, at a CAGR of 5.54%. Growth is fueled by expanding chain cafes, specialty coffee methods like cold brew, and rising homegrown brands. However, rising coffee...

Market News
Neutral
27 minutes ago
FDA grants orphan drug status to sovleplenib for rare autoimmune disease ITP treatment

FDA grants orphan drug status to sovleplenib for rare autoimmune disease ITP treatment

HUTCHMED announced that the US FDA has granted orphan drug designation to sovleplenib for treating primary immune thrombocytopenia (ITP), a rare autoimmune disorder causing low platelet counts and bleeding risks. This status provides benefits like 7 ...

Market News
Bullish
27 minutes ago
LUXEED hosts global media test drive showcasing advanced tech and luxury in new LLounge and Stormax models.

LUXEED hosts global media test drive showcasing advanced tech and luxury in new LLounge and Stormax models.

LUXEED held a global media test drive event at Chery's International Headquarters in Vu Hồ, featuring the luxury MPV LLounge and the high-performance Stormax SUV. Media representatives and influencers from UAE, Thailand, and Indonesia experienced a 1...

Market News
Bullish
27 minutes ago
Law firm investigates NVE Corporation over sharp Q2 revenue drop and stock plunge.

Law firm investigates NVE Corporation over sharp Q2 revenue drop and stock plunge.

Kirby McInerney LLP is investigating NVE Corporation for possible violations of federal securities laws after the company reported a 47% revenue decline and a 33.7% stock price drop following its Q2 fiscal 2027 results. The revenue fall was attribute...

Market News
Bearish
2 hours ago
Fort Technology warned by Nasdaq for falling below $1 minimum bid price, given 180 days to comply.

Fort Technology warned by Nasdaq for falling below $1 minimum bid price, given 180 days to comply.

Fort Technology received a notification from Nasdaq on October 13, 2026, stating it failed to meet the minimum bid price requirement of $1.00 per share over the past 30 days. The company has 180 days, until April 12, 2027, to restore its share price ...

Market News
Bearish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App